Overview

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

Status:
Completed
Trial end date:
2016-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.
Phase:
Early Phase 1
Details
Lead Sponsor:
Stanford University
Collaborators:
National Cancer Institute (NCI)
University Hospitals Cleveland Medical Center